Decursin Suppresses Esophageal Squamous Cell Carcinoma Progression via Orchestrated Cell Cycle Deceleration, Apoptotic Activation, and Oncoprotein Degradation DOI Open Access
Chen Fang,

Lin Wu,

Xiangzhe Yang

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(11), С. 5391 - 5391

Опубликована: Июнь 4, 2025

Esophageal squamous cell carcinoma (ESCC) remains a lethal malignancy with limited therapeutic options. This study investigated the antitumor efficacy and mechanisms of decursin, natural pyranocoumarin derivative, against ESCC. In vitro analyses demonstrated that decursin selectively inhibited ESCC viability (IC50: 14.62 ± 0.61–26.20 2.11 μM across TE-1, KYSE-30, KYSE-150 lines) without affecting normal esophageal epithelial cells (Het-1A). Decursin (10 μM) suppressed colony formation, impaired wound healing (p < 0.001 at 48 h), reduced Transwell migration/invasion in cells. Subcutaneous xenograft models revealed significant tumor growth inhibition 0.01) treatment mg/kg, intraperitoneal), accompanied by no systemic toxicity. Mechanistically, induced G0/G1 cycle deceleration apoptosis through ubiquitin–proteasome-mediated degradation oncoproteins TP63 SOX2. Time- dose-dependent protein suppression was reversed proteasome inhibitor MG-132, but unaffected lysosomal inhibition. These findings establish as promising agent for ESCC, functioning via proteasomal key oncogenic drivers, provide rationale decursin’s further development targeted monotherapy or chemosensitizer multimodal regimens.

Язык: Английский

SQYC formula improves the efficacy of PD-1 monoclonal antibodies in MSS colorectal cancer by regulating dendritic cell mitophagy via the PINK1-Parkin pathway DOI Creative Commons
Hong Wang, Y. Y. Ji, Shan Deng

и другие.

Phytomedicine, Год журнала: 2025, Номер 138, С. 156388 - 156388

Опубликована: Янв. 11, 2025

Язык: Английский

Процитировано

0

Exploring the Underlying Mechanism of Weiling Decoction Alleviates Cold-Dampness Diarrhea Based on Network Pharmacology, Transcriptomics, Molecular Docking and Experimental Validation DOI Creative Commons
Y Zhang, Shuai Zhang, Yimeng Fan

и другие.

Pharmaceuticals, Год журнала: 2025, Номер 18(1), С. 109 - 109

Опубликована: Янв. 16, 2025

Background: Cold-dampness diarrhea (CDD) is a common gastrointestinal disorder in children, characterized by and intestinal barrier dysfunction. Weiling decoction (WLD) frequently used clinical practice to treat CDD, condition triggered multiple factors. However, the molecular mechanisms underlying its therapeutic effects remain poorly understood. Objectives: This study aimed evaluate efficacy of WLD treating CDD elucidate potential mechanisms. Methods: UPLC-HRMS/MS was employed identify chemical constituents absorption components plasma WLD-treated rats. Additionally, rat model established assess through comprehensive approach. To these effects, network pharmacology transcriptomic analyses were performed signaling pathways associated with alleviation. Molecular docking flow cytometry assays subsequently utilized validate identified pathways. Results: A total 223 detected WLD, 49 rats UPLC-HRMS/MS. treatment significantly alleviated symptoms reduced damage, diminished inflammatory response. influenced key genes immune-related revealed strong binding affinities between main targets within Flow cytometry, along analysis cytokines transcription factors, demonstrated that modulated balance Th1/Th2 Th17/Treg cell populations. Conclusions: provides first evidence alleviates regulating These findings offer theoretical basis for future investigations into CDD.

Язык: Английский

Процитировано

0

Deep Learning-based Multi-Brain Capsule network for Next-Gen Clinical Emotion Recognition using EEG Signals DOI Creative Commons
Ravinder Dahiya,

G Mamatha,

Shila Jawale

и другие.

Neuroscience Informatics, Год журнала: 2025, Номер 5(2), С. 100203 - 100203

Опубликована: Апрель 28, 2025

Язык: Английский

Процитировано

0

Decursin Suppresses Esophageal Squamous Cell Carcinoma Progression via Orchestrated Cell Cycle Deceleration, Apoptotic Activation, and Oncoprotein Degradation DOI Open Access
Chen Fang,

Lin Wu,

Xiangzhe Yang

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(11), С. 5391 - 5391

Опубликована: Июнь 4, 2025

Esophageal squamous cell carcinoma (ESCC) remains a lethal malignancy with limited therapeutic options. This study investigated the antitumor efficacy and mechanisms of decursin, natural pyranocoumarin derivative, against ESCC. In vitro analyses demonstrated that decursin selectively inhibited ESCC viability (IC50: 14.62 ± 0.61–26.20 2.11 μM across TE-1, KYSE-30, KYSE-150 lines) without affecting normal esophageal epithelial cells (Het-1A). Decursin (10 μM) suppressed colony formation, impaired wound healing (p < 0.001 at 48 h), reduced Transwell migration/invasion in cells. Subcutaneous xenograft models revealed significant tumor growth inhibition 0.01) treatment mg/kg, intraperitoneal), accompanied by no systemic toxicity. Mechanistically, induced G0/G1 cycle deceleration apoptosis through ubiquitin–proteasome-mediated degradation oncoproteins TP63 SOX2. Time- dose-dependent protein suppression was reversed proteasome inhibitor MG-132, but unaffected lysosomal inhibition. These findings establish as promising agent for ESCC, functioning via proteasomal key oncogenic drivers, provide rationale decursin’s further development targeted monotherapy or chemosensitizer multimodal regimens.

Язык: Английский

Процитировано

0